Medicare Advantage (MA) provides accountable care organizations (ACOs) with benefits that aren’t available in Medicare’s ACO program, explained Kim Kauffman, MPH, vice president of value-based care at Summit Medical Group.
Medicare Advantage (MA) provides accountable care organizations (ACOs) with benefits that aren’t available in Medicare’s ACO program, explained Kim Kauffman, MPH, vice president of value-based care at Summit Medical Group.
Transcript
Why should ACOs be involved in Medicare Advantage? What benefits does it have over the Medicare Shared Savings Program?
I think that Medicare advantage has some levers to control the total cost of care that are just not available in the Medicare Shared Savings Program [MSSP] ACOs. Things like there’s contracted network providers, there are levers that have to do with prior authorizations and or referral patterns that are quite helpful in controlling the total cost of care. Contracted rates is huge—total cost of care is a function of both utilization and contracted rates and so in MA you have more room. The other thing piece I think, particularly from a patient perspective, Medicare Advantage has supplemental benefits that are avaible to the patients that are just not there in traditional Medicare.
There’s some other levers in Medicare Advantage that are not avaible in MSSP and those would have to do with the top line, risk adjustment for example. There’s no top end, there’s no maximum risk adjustment in Medicare Advantage the way there is in Medicare Shared Savings Program. There are, however, 2 downward adjustments and risk adjustment for Medicare Advantage because risk adjustment is outpacing risk adjustment in fee for service.
Also, in terms of cash flow if an organization chooses to partner with a health plan there is much less cash outlay than there is in a Medicare Shared Savings Program, where the provider organization is doing it all on their own. Finally, in shared savings in the Medicare Advantage context you are actually in a position where you can negotiate what is the threshold, what is the upside, what is the downside split. And, certainly, what comes down from the hill in Medicare Shared Savings Program that that is what it is.
Final point I would make though is that while Medicare Advantage has some opportunities to better control total cost of care, not all patients are going to want to be in a Medicare Advantage plan and that’s why I think it’s important that provider organizations have a strategy that includes some element of Medicare Shared Savings Program and MA.
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Value-Based Care Is Key to Bringing Cardiology Breakthroughs to Those Who Will Benefit Most
March 13th 2025On December 10, 2024, cardiologists, researchers, and value-based care experts gathered in Dallas, Texas, to discuss best practices for implementing advances in cardiology care with a value-based mindset, spanning the care continuum from prevention to treatment.
Read More
Advances in Gene Therapy, Neuroregeneration at the Forefront of MDA 2025
March 13th 2025Look ahead to this year's Muscular Dystrophy Association (MDA) meeting, which will feature discussions on the latest gene therapies, clinical trial data, policy considerations, and more in the realm of neuromuscular disease.
Read More
Late-Breaking Antiviral Session Features Phase 3 Results on Efficacy of Doravirine/Islatravir
March 13th 2025The combination of doravirine plus islatravir was noninferior to bictegravir/emtricitabine/tenofovir alafenamide and oral antiretroviral therapy in patients who switched to doravirine plus islatravir.
Read More